Sionna Therapeutics Inc
SIONHealthcare|Biotechnology|USA
$45.29
+0.29 (+0.65%)
Tangible Book
$6.39
About
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Stock Price
+116.3%(1Y)
Pipeline Summary
2 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Active: 1Recruiting: 1
Active Trials (2)
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
NCT07108153Cystic Fibrosis (CF)
Phase 2Active
Enrollment: 16 participants
Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.
NCT07035990Cystic Fibrosis (CF)
Phase 1Recruiting
Enrollment: 144 participants
BioScore
5.3/10
Watchlist
Ownership
Recent Insider Trades
Thompson Peter A.SELL
2026-07-0785,918 shares @ $44.86
ORBIMED ADVISORS LLCSELL
2026-07-0785,918 shares @ $44.86
Fitzpatrick JenniferSELL
2026-07-0610,250 shares @ $43.6
Thompson Peter A.SELL
2026-06-30115,844 shares @ $45.5
ORBIMED ADVISORS LLCSELL
2026-06-30115,844 shares @ $45.5
Data last updated: Jul 13, 2026, 12:43 PM